Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal Dynamics of Polyglutamine-Expanded ATXN3 in Biofluids of Spinocerebellar Ataxia Type 3.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

A repeat expansion in GOLGA8A is a major risk factor for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions.

Nature genetics·2026
Same author

Novel Aggressive Subtype of Multiple System Atrophy Identified by Unsupervised Machine Learning.

Annals of neurology·2026
Same author

Association between Human Leukocyte Antigen Alleles and Neuropathological Outcomes in Lewy Body Disease.

Annals of neurology·2025
Same author

Early subtypes and progressions of progressive supranuclear palsy: a data-driven brain bank study.

Journal of neurology·2025
Same author

Five-Year Outcomes from Deep Brain Stimulation of the Subthalamic Nucleus for Parkinson Disease.

JAMA neurology·2025
Same journal

Ictal Asystole or Vasovagal Syncope? A Diagnostic Pitfall in Pediatric Drug-Resistant Epilepsy.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

Validation of an ICD-10 Code for Diplopia in the Emergency Department: A Retrospective Cohort Study.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

Practice Patterns and Care Gaps in Lennox Gastaut Syndrome: A call for Action.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

Isolated Achiasma Discovered at Age 86: A Rare Cause of see-saw nystagmus and bitemporal hemianopia.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

Post-Stroke Parakinesia Brachialis Oscitans: Clinical Insights from a Case Series.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

A Neuronal Perspective.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
See all related articles

Related Experiment Videos

Depression in Parkinson's disease.

Barbara Jasinska-Myga1, John D Putzke, Christian Wider

  • 1Department of Neurology, Mayo Clinic, Jacksonville, Florida 32224, USA.

The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques
|February 23, 2010
PubMed
Summary
This summary is machine-generated.

Depression is common in Parkinson's disease (PD). Longer disease duration, functional decline, and a family history of motor neuron disease (MND) increase depression risk in PD patients.

Related Experiment Videos

Area of Science:

  • Neurology
  • Psychiatry

Background:

  • Depression is a common comorbidity in Parkinson's disease (PD).
  • Depression in PD can manifest before or after motor symptoms and is often undertreated.
  • Identifying predictive factors for depression is crucial for timely intervention in PD patients.

Purpose of the Study:

  • To identify factors predicting the onset of depression in individuals with Parkinson's disease.
  • To enhance early detection and management of depression in PD.

Main Methods:

  • A longitudinal study of 685 Parkinson's disease patients followed by a single neurologist.
  • Depression diagnosis based on clinical assessment and antidepressant use.
  • Analysis of demographic, clinical, and historical factors as predictors of depression onset.

Main Results:

  • 72% of Parkinson's disease patients developed depression within 10 years of symptom onset.
  • Mean time to depression onset was 7.9 years (median 5.7 years).
  • Factors associated with depression included longer PD duration, impaired daily living activities, and a family history of motor neuron disease (MND).

Conclusions:

  • A significant proportion of Parkinson's disease patients experience depression.
  • Initial clinical factors were not strong predictors of depression risk.
  • Clinicians should maintain vigilance for depression, especially in patients with longer disease duration, functional limitations, or a family history of MND.